We envision a world where
DISEASES DRIVEN BY INFLAMMATION are treatable at their source

Targeting the NLRP3 inflammasome

OUR DIFFERENTIATED APPROACH FOR AGE-RELATED CARDIOMETABOLIC AND NEUROINFLAMMATORY DISEASES

Inflammation driven by chronic NLRP3 activation accelerates age-related cardiometabolic and neuroinflammatory diseases that impact billions of people. NLRP3 is a powerful upstream driver of the IL-1β/IL-18 inflammation pathways that intensify with age. NodThera’s brain-penetrant, oral small-molecule NLRP3 inhibitors are designed to normalize NLRP3 activity throughout the body and in the brain, reducing disease-causing inflammation while preserving the ability to fight infections.

Meet the experts

For a decade, NodThera has led the NLRP3 field, advancing the science from discovery through to clinical proof of concept. NodThera has played a key role in shaping the clinical landscape of NLRP3 inhibition, achieving multiple research and clinical milestones, including an early published demonstration of anti-neuroinflammatory activity for an oral NLRP3 inhibitor. As NodThera advances toward Phase 3, the team combines deep NLRP3 expertise with the creativity and rigor needed to translate scientific innovation into real-world medicines for patients.